Disulfiram Inclusion Complexes - A Nebulization Approach to Fight COVID-19

Abstract

Disulfiram (DS) has an excellent anti-viral activity; however, its low water-solubility and first-pass metabolism are limiting its clinical applications. Cyclodextrins (CDs) have been used as solubility enhancers and carriers of DS proposed for inhalation to treat SARS-CoV-19. Two types of CDs (hydroxypropyl β-cyclodextrin and sulfobutyl ether β-cyclodextrin) were used to form inclusion complexes with DS, and drug solubility was assessed using spectrophotometric analytical method. Formulations were freeze-dried and characterized using DSC, TGA and FTIR. Nebulization technique was used to assess the potential for generating aerosols. All inclusion complexes are proved to be suitable for inhalation, therefore, potentially effective therapy for further investigation against SARS-CoV-19 is shown. 

Keywords

disulfiram, β-cyclodextrin, SARS-CoV-19, nebulization

How to Cite

Pereira, A. M., Kaya, A., Alves, D., Ansari-Fard, N. & Najlah, M., (2022) “Disulfiram Inclusion Complexes - A Nebulization Approach to Fight COVID-19”, British Journal of Pharmacy 7(2). doi: https://doi.org/10.5920/bjpharm.1149

388

Views

82

Downloads

Share

Authors

Ana Maria Pereira (Anglia Ruskin University)
Ayse Kaya (Anglia Ruskin University)
Dan Alves (Anglia Ruskin University)
Niusha Ansari-Fard (Anglia Ruskin University)
Mohammad Najlah (Anglia Ruskin University)

Download

Issue

Dates

Licence

Creative Commons Attribution 4.0

Identifiers

Peer Review

This article has been peer reviewed.

File Checksums (MD5)

  • Full text: 938c119aae9737ec7ed577afb11dd17b